Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

This study has been completed.
Sponsor:
Collaborators:
Ministry of Health, China
Hepatic Surgery Clinical Research Centre of Hubei, China
Information provided by:
Huazhong University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00733200
First received: August 8, 2008
Last updated: December 10, 2009
Last verified: August 2008

August 8, 2008
December 10, 2009
Not Provided
Not Provided
On multivariate analysis, prognostic factors significantly impacted on long-term survival were UICC tumor stage and histopathologic grade.
Same as current
Complete list of historical versions of study NCT00733200 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?
Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

The investigators conducted a prospective study to determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in 138 patients with hilar cholangiocarcinoma. In selected patients, minor liver resection was a good treatment.

Objective: To determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in patients with hilar cholangiocarcinoma (HC).

Summary Background Data: For HC treated with hepatectomy, the extent of liver resection remains controversial despite extensive studies.

Methods: From January 2000 to December 2007, we prospectively studied patients who received surgical treatment for HC. Of the 187 patients who were surgically treated, 138 (73.8%) underwent resection with a curative intent. Minor hepatectomy was carried out in 93 patients who had Bismuth-Corlette types I, II and III HC without hepatic artery/portal vein invasion; and major hepatectomy in 45 patients who had type III HC with hepatic artery/portal vein invasion, or type IV HC.

Interventional
Not Provided
Not Provided
  • Cholangiocarcinoma
  • Surgical Treatment
  • Hepatectomy
Procedure: Minor or Major Liver Resection
No Intervention: Control group
Intervention: Procedure: Minor or Major Liver Resection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Criteria for resectability were absence of peritoneal or liver metastases, tumor extension to beyond secondary biliary branches bilaterally, tumor extension to secondary portal venous branches bilaterally

Exclusion Criteria:

  • not in accordance with the above criteria
Both
26 Years to 72 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00733200
chenxp002
Yes
Not Provided
Huazhong University of Science and Technology
  • Ministry of Health, China
  • Hepatic Surgery Clinical Research Centre of Hubei, China
Not Provided
Huazhong University of Science and Technology
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP